Metabolic Diseases  >>  Cholebine (colestilan)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cholebine (colestilan) / Mitsubishi Tanabe
NCT00506441: A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Completed
3
245
US
MCI-196, Colestilan(INN), Colestimide(JAN), CHOLEBINE®, BindRen®, Placebo
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
09/09
09/09
NCT00416520 / 2006-003323-37: A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

Completed
3
336
Europe, RoW
MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Placebo, Another phosphate binder (Sevelamer)
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Hyperphosphatemia
11/09
11/09
NCT00542386 / 2006-006535-53: A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

Completed
3
642
Europe, RoW
MCI-196, Colestilan(INN),, Colestimide(JAN), CHOLEBINE®, BindRen®, Placebo
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Dyslipidemia
11/09
11/09
NCT00858637 / 2007-003364-21: Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Completed
3
260
Europe, RoW
MCI-196, Colestilan(INN), Colestimide(JAN), CHOLEBINE®, BindRen®, Placebo of Simvastatin, Simvastatin, Placebo of MCI-196
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease
03/10
03/10
NCT00542815 / 2006-003330-15: A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Completed
3
632
Europe, RoW
MCI-196, Colestilan(INN), Colestimide(JAN), CHOLEBINE®, BindRen®, Another Phosphate binder (Sevelamer)
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
08/10
08/10
NCT00772382: Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Completed
3
116
US, Canada
MCI-196, Colestilan(INN), Colestimide(JAN), CHOLEBINE®, BindRen®
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
08/10
08/10
NCT00451295 / 2006-003324-11: A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia

Terminated
3
6
Europe, RoW
MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®), Placebo
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
01/11
01/11
NCT01818687 / 2012-002582-35: Safety and Tolerability Study of MCI-196

Terminated
3
4
Europe
colestilan, BindRen
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Not on Dialysis, Hyperphosphatemia, Paediatric
12/14
12/14
NCT01814917 / 2012-002583-27: Long-term Extension Study of MCI-196

Terminated
3
6
Europe
colestilan, BindRen, CBPB
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
12/14
12/14
NCT01814904 / 2012-002581-12: Dose-finding Study of MCI-196

Terminated
3
10
Europe
colestilan-L, BindRen, colestilan-M, colestilan-H, CBPB
Mitsubishi Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
01/15
01/15

Download Options